XNASKA
Market cap7mUSD
Sep 18, Last price
0.57USD
Name
Kineta Inc
Chart & Performance
P/E
—
P/S
1.29
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
109.34%
Rev. gr., 5y
13.89%
Revenues
5m
+178.65%
Net income
-14m
L-77.64%
CFO
-16m
L-14.82%
Dividend
Dec 19, 20221.43 USD/sh
Earnings
Mar 19, 2025
Profile
Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 5,442 178.65% | 1,953 -78.52% | 9,091 -13.32% | ||||||
Cost of revenue | 21,165 | 44,218 | 20,853 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (15,723) | (42,265) | (11,762) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 23 | (386) | 143 | ||||||
Tax Rate | |||||||||
NOPAT | (15,746) | (41,879) | (11,905) | ||||||
Net income | (14,099) -77.64% | (63,067) 427.32% | (11,960) -13.81% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 8,561 | 8,988 | 16,713 | ||||||
BB yield | -21.34% | -28.73% | |||||||
| Debt | |||||||||
Debt current | 1,714 | 883 | 10,763 | ||||||
Long-term debt | 697 | 2,891 | 13,171 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (3,447) | (9,494) | 12,715 | ||||||
| Cash flow | |||||||||
Cash from operating activities | (16,209) | (19,029) | (17,853) | ||||||
CAPEX | (71) | ||||||||
Cash from investing activities | 331 | 9,270 | |||||||
Cash from financing activities | 8,468 | 11,808 | 17,527 | ||||||
FCF | (14,758) | (41,278) | (11,263) | ||||||
| Balance | |||||||||
Cash | 5,858 | 13,143 | 11,144 | ||||||
Long term investments | 125 | 75 | |||||||
Excess cash | 5,586 | 13,170 | 10,764 | ||||||
Stockholders' equity | (165,610) | (151,536) | (88,084) | ||||||
Invested Capital | 170,533 | 158,367 | 97,822 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 11,054 | 4,926 | 1,469 | ||||||
Price | 3.63 -42.83% | 6.35 | |||||||
Market cap | 40,126 28.28% | 31,280 | |||||||
EV | 36,848 | 21,932 | |||||||
EBITDA | (15,714) | (42,192) | (11,683) | ||||||
EV/EBITDA | |||||||||
Interest | 337 | 3,737 | 1,293 | ||||||
Interest/NOPBT | |||||||||